Global Kidney Cancer Drugs

Kidney Cancer Drugs Comprehensive Study by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Other), Application (Hospitals, Clinics, Research Center, Other), Therapy (Targeted Therapy, Chemotherapy, Immunotherapy) Players and Region - Global Market Outlook to 2030

Kidney Cancer Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Kidney Cancer Drugs
Kidney cancer is also called renal cancer. It is a disease in which kidney cells become malignant and grow out of control, forming a tumor. It first appears in the lining of tiny tubes in the kidney and this type of kidney cancer is known as renal cell carcinoma. Most of the kidney cancers are found before they spread to distant organs. The drug treatment for kidney cancer is based on the stage and grade of cancer and the patient’s general health.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Kidney Cancer Drugs market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Kidney Cancer Drugs Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Kidney Cancer Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Abbott Laboratories (United States), GlaxoSmithKline PLC (United Kingdom), Novartis AG (Switzerland), Merck KGaA (Germany), Bayer AG (Germany), Active Biotech (Sweden), Amgen (United States), Cipla Limited (India) and Roche Holding AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Genentech (United States), Prometheus Laboratories (United States), Exelixis Inc. (United States), AVEO Oncology (United States) and Immatics Biotechnologies (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Kidney Cancer Drugs market by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin) and Other), Application (Hospitals, Clinics, Research Center and Other) and Region.



On the basis of geography, the market of Kidney Cancer Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Targeted Therapy will boost the Kidney Cancer Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the Kidney Cancer Treatment

Market Growth Drivers:
Increase in the Prevalence of Kidney Cancer, Development of New Diagnostic Centers and Hospitals and Increase in Healthcare Expenditure

Challenges:
Lack of Awareness among People in Developing Countries

Restraints:
High Cost of Kidney Cancer Drugs

Opportunities:
Rising Aging Population Worldwide and Development of Healthcare Infrastructure in Emerging Economies

Market Leaders and their expansionary development strategies
In January 2019, GlaxoSmithKline plc. announced that it has successfully completed the acquisition of TESARO, Inc. a commercial-stage biopharmaceutical company.
In May 2019, Merck KGaA and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO (avelumab) in combination with INLYTA (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).


Key Target Audience
Kidney Cancer Drugs Manufacturers, Research Professionals, Emerging Companies, Distributors, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Nexavar (Sorafenib)
  • Sutent (Sunitinib)
  • Afinitor (Everolimus)
  • Votrient (Pazopanib)
  • Avastin (Bevacizumab)
  • Inlyta (Axitinib)
  • Torisel (Temsirolimus)
  • Proleukin (Aldesleukin)
  • Other
By Application
  • Hospitals
  • Clinics
  • Research Center
  • Other
By Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Kidney Cancer
      • 3.2.2. Development of New Diagnostic Centers and Hospitals
      • 3.2.3. Increase in Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among People in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Kidney Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kidney Cancer Drugs, by Type, Application, Therapy and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Kidney Cancer Drugs (Value)
      • 5.2.1. Global Kidney Cancer Drugs by: Type (Value)
        • 5.2.1.1. Nexavar (Sorafenib)
        • 5.2.1.2. Sutent (Sunitinib)
        • 5.2.1.3. Afinitor (Everolimus)
        • 5.2.1.4. Votrient (Pazopanib)
        • 5.2.1.5. Avastin (Bevacizumab)
        • 5.2.1.6. Inlyta (Axitinib)
        • 5.2.1.7. Torisel (Temsirolimus)
        • 5.2.1.8. Proleukin (Aldesleukin)
        • 5.2.1.9. Other
      • 5.2.2. Global Kidney Cancer Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Center
        • 5.2.2.4. Other
      • 5.2.3. Global Kidney Cancer Drugs by: Therapy (Value)
        • 5.2.3.1. Targeted Therapy
        • 5.2.3.2. Chemotherapy
        • 5.2.3.3. Immunotherapy
      • 5.2.4. Global Kidney Cancer Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Kidney Cancer Drugs (Volume)
      • 5.3.1. Global Kidney Cancer Drugs by: Type (Volume)
        • 5.3.1.1. Nexavar (Sorafenib)
        • 5.3.1.2. Sutent (Sunitinib)
        • 5.3.1.3. Afinitor (Everolimus)
        • 5.3.1.4. Votrient (Pazopanib)
        • 5.3.1.5. Avastin (Bevacizumab)
        • 5.3.1.6. Inlyta (Axitinib)
        • 5.3.1.7. Torisel (Temsirolimus)
        • 5.3.1.8. Proleukin (Aldesleukin)
        • 5.3.1.9. Other
      • 5.3.2. Global Kidney Cancer Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Research Center
        • 5.3.2.4. Other
      • 5.3.3. Global Kidney Cancer Drugs by: Therapy (Volume)
        • 5.3.3.1. Targeted Therapy
        • 5.3.3.2. Chemotherapy
        • 5.3.3.3. Immunotherapy
      • 5.3.4. Global Kidney Cancer Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Kidney Cancer Drugs (Price)
      • 5.4.1. Global Kidney Cancer Drugs by: Type (Price)
  • 6. Kidney Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Active Biotech (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Roche Holding AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Kidney Cancer Drugs Sale, by Type, Application, Therapy and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Kidney Cancer Drugs (Value)
      • 7.2.1. Global Kidney Cancer Drugs by: Type (Value)
        • 7.2.1.1. Nexavar (Sorafenib)
        • 7.2.1.2. Sutent (Sunitinib)
        • 7.2.1.3. Afinitor (Everolimus)
        • 7.2.1.4. Votrient (Pazopanib)
        • 7.2.1.5. Avastin (Bevacizumab)
        • 7.2.1.6. Inlyta (Axitinib)
        • 7.2.1.7. Torisel (Temsirolimus)
        • 7.2.1.8. Proleukin (Aldesleukin)
        • 7.2.1.9. Other
      • 7.2.2. Global Kidney Cancer Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Center
        • 7.2.2.4. Other
      • 7.2.3. Global Kidney Cancer Drugs by: Therapy (Value)
        • 7.2.3.1. Targeted Therapy
        • 7.2.3.2. Chemotherapy
        • 7.2.3.3. Immunotherapy
      • 7.2.4. Global Kidney Cancer Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Kidney Cancer Drugs (Volume)
      • 7.3.1. Global Kidney Cancer Drugs by: Type (Volume)
        • 7.3.1.1. Nexavar (Sorafenib)
        • 7.3.1.2. Sutent (Sunitinib)
        • 7.3.1.3. Afinitor (Everolimus)
        • 7.3.1.4. Votrient (Pazopanib)
        • 7.3.1.5. Avastin (Bevacizumab)
        • 7.3.1.6. Inlyta (Axitinib)
        • 7.3.1.7. Torisel (Temsirolimus)
        • 7.3.1.8. Proleukin (Aldesleukin)
        • 7.3.1.9. Other
      • 7.3.2. Global Kidney Cancer Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Research Center
        • 7.3.2.4. Other
      • 7.3.3. Global Kidney Cancer Drugs by: Therapy (Volume)
        • 7.3.3.1. Targeted Therapy
        • 7.3.3.2. Chemotherapy
        • 7.3.3.3. Immunotherapy
      • 7.3.4. Global Kidney Cancer Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Kidney Cancer Drugs (Price)
      • 7.4.1. Global Kidney Cancer Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kidney Cancer Drugs: by Type(USD Million)
  • Table 2. Kidney Cancer Drugs Nexavar (Sorafenib) , by Region USD Million (2018-2023)
  • Table 3. Kidney Cancer Drugs Sutent (Sunitinib) , by Region USD Million (2018-2023)
  • Table 4. Kidney Cancer Drugs Afinitor (Everolimus) , by Region USD Million (2018-2023)
  • Table 5. Kidney Cancer Drugs Votrient (Pazopanib) , by Region USD Million (2018-2023)
  • Table 6. Kidney Cancer Drugs Avastin (Bevacizumab) , by Region USD Million (2018-2023)
  • Table 7. Kidney Cancer Drugs Inlyta (Axitinib) , by Region USD Million (2018-2023)
  • Table 8. Kidney Cancer Drugs Torisel (Temsirolimus) , by Region USD Million (2018-2023)
  • Table 9. Kidney Cancer Drugs Proleukin (Aldesleukin) , by Region USD Million (2018-2023)
  • Table 10. Kidney Cancer Drugs Other , by Region USD Million (2018-2023)
  • Table 11. Kidney Cancer Drugs: by Application(USD Million)
  • Table 12. Kidney Cancer Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 13. Kidney Cancer Drugs Clinics , by Region USD Million (2018-2023)
  • Table 14. Kidney Cancer Drugs Research Center , by Region USD Million (2018-2023)
  • Table 15. Kidney Cancer Drugs Other , by Region USD Million (2018-2023)
  • Table 16. Kidney Cancer Drugs: by Therapy(USD Million)
  • Table 17. Kidney Cancer Drugs Targeted Therapy , by Region USD Million (2018-2023)
  • Table 18. Kidney Cancer Drugs Chemotherapy , by Region USD Million (2018-2023)
  • Table 19. Kidney Cancer Drugs Immunotherapy , by Region USD Million (2018-2023)
  • Table 20. South America Kidney Cancer Drugs, by Country USD Million (2018-2023)
  • Table 21. South America Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 22. South America Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 23. South America Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 24. Brazil Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 25. Brazil Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 26. Brazil Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 27. Argentina Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 28. Argentina Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 29. Argentina Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 30. Rest of South America Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 33. Asia Pacific Kidney Cancer Drugs, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 37. China Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 38. China Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 39. China Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 40. Japan Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 41. Japan Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 42. Japan Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 43. India Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 44. India Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 45. India Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 46. South Korea Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 47. South Korea Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 48. South Korea Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 49. Taiwan Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 50. Taiwan Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 51. Taiwan Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 52. Australia Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 53. Australia Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 54. Australia Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 58. Europe Kidney Cancer Drugs, by Country USD Million (2018-2023)
  • Table 59. Europe Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 60. Europe Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 61. Europe Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 62. Germany Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 63. Germany Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 64. Germany Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 65. France Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 66. France Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 67. France Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 68. Italy Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 69. Italy Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 70. Italy Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 71. United Kingdom Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 72. United Kingdom Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 73. United Kingdom Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 74. Netherlands Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 75. Netherlands Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 76. Netherlands Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 77. Rest of Europe Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 78. Rest of Europe Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 79. Rest of Europe Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 80. MEA Kidney Cancer Drugs, by Country USD Million (2018-2023)
  • Table 81. MEA Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 82. MEA Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 83. MEA Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 84. Middle East Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 85. Middle East Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 86. Middle East Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 87. Africa Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 88. Africa Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 89. Africa Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 90. North America Kidney Cancer Drugs, by Country USD Million (2018-2023)
  • Table 91. North America Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 92. North America Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 93. North America Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 94. United States Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 95. United States Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 96. United States Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 97. Canada Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 98. Canada Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 99. Canada Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 100. Mexico Kidney Cancer Drugs, by Type USD Million (2018-2023)
  • Table 101. Mexico Kidney Cancer Drugs, by Application USD Million (2018-2023)
  • Table 102. Mexico Kidney Cancer Drugs, by Therapy USD Million (2018-2023)
  • Table 103. Kidney Cancer Drugs Sales: by Type(K Units)
  • Table 104. Kidney Cancer Drugs Sales Nexavar (Sorafenib) , by Region K Units (2018-2023)
  • Table 105. Kidney Cancer Drugs Sales Sutent (Sunitinib) , by Region K Units (2018-2023)
  • Table 106. Kidney Cancer Drugs Sales Afinitor (Everolimus) , by Region K Units (2018-2023)
  • Table 107. Kidney Cancer Drugs Sales Votrient (Pazopanib) , by Region K Units (2018-2023)
  • Table 108. Kidney Cancer Drugs Sales Avastin (Bevacizumab) , by Region K Units (2018-2023)
  • Table 109. Kidney Cancer Drugs Sales Inlyta (Axitinib) , by Region K Units (2018-2023)
  • Table 110. Kidney Cancer Drugs Sales Torisel (Temsirolimus) , by Region K Units (2018-2023)
  • Table 111. Kidney Cancer Drugs Sales Proleukin (Aldesleukin) , by Region K Units (2018-2023)
  • Table 112. Kidney Cancer Drugs Sales Other , by Region K Units (2018-2023)
  • Table 113. Kidney Cancer Drugs Sales: by Application(K Units)
  • Table 114. Kidney Cancer Drugs Sales Hospitals , by Region K Units (2018-2023)
  • Table 115. Kidney Cancer Drugs Sales Clinics , by Region K Units (2018-2023)
  • Table 116. Kidney Cancer Drugs Sales Research Center , by Region K Units (2018-2023)
  • Table 117. Kidney Cancer Drugs Sales Other , by Region K Units (2018-2023)
  • Table 118. Kidney Cancer Drugs Sales: by Therapy(K Units)
  • Table 119. Kidney Cancer Drugs Sales Targeted Therapy , by Region K Units (2018-2023)
  • Table 120. Kidney Cancer Drugs Sales Chemotherapy , by Region K Units (2018-2023)
  • Table 121. Kidney Cancer Drugs Sales Immunotherapy , by Region K Units (2018-2023)
  • Table 122. South America Kidney Cancer Drugs Sales, by Country K Units (2018-2023)
  • Table 123. South America Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 124. South America Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 125. South America Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 126. Brazil Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 127. Brazil Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 128. Brazil Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 129. Argentina Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 130. Argentina Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 131. Argentina Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 132. Rest of South America Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 133. Rest of South America Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 134. Rest of South America Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 135. Asia Pacific Kidney Cancer Drugs Sales, by Country K Units (2018-2023)
  • Table 136. Asia Pacific Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 137. Asia Pacific Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 138. Asia Pacific Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 139. China Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 140. China Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 141. China Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 142. Japan Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 143. Japan Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 144. Japan Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 145. India Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 146. India Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 147. India Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 148. South Korea Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 149. South Korea Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 150. South Korea Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 151. Taiwan Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 152. Taiwan Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 153. Taiwan Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 154. Australia Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 155. Australia Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 156. Australia Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 157. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 158. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 159. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 160. Europe Kidney Cancer Drugs Sales, by Country K Units (2018-2023)
  • Table 161. Europe Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 162. Europe Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 163. Europe Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 164. Germany Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 165. Germany Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 166. Germany Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 167. France Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 168. France Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 169. France Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 170. Italy Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 171. Italy Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 172. Italy Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 173. United Kingdom Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 174. United Kingdom Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 175. United Kingdom Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 176. Netherlands Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 177. Netherlands Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 178. Netherlands Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 179. Rest of Europe Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 180. Rest of Europe Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 181. Rest of Europe Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 182. MEA Kidney Cancer Drugs Sales, by Country K Units (2018-2023)
  • Table 183. MEA Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 184. MEA Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 185. MEA Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 186. Middle East Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 187. Middle East Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 188. Middle East Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 189. Africa Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 190. Africa Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 191. Africa Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 192. North America Kidney Cancer Drugs Sales, by Country K Units (2018-2023)
  • Table 193. North America Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 194. North America Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 195. North America Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 196. United States Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 197. United States Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 198. United States Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 199. Canada Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 200. Canada Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 201. Canada Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 202. Mexico Kidney Cancer Drugs Sales, by Type K Units (2018-2023)
  • Table 203. Mexico Kidney Cancer Drugs Sales, by Application K Units (2018-2023)
  • Table 204. Mexico Kidney Cancer Drugs Sales, by Therapy K Units (2018-2023)
  • Table 205. Kidney Cancer Drugs: by Type(USD/Units)
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Kidney Cancer Drugs: by Type(USD Million)
  • Table 217. Kidney Cancer Drugs Nexavar (Sorafenib) , by Region USD Million (2025-2030)
  • Table 218. Kidney Cancer Drugs Sutent (Sunitinib) , by Region USD Million (2025-2030)
  • Table 219. Kidney Cancer Drugs Afinitor (Everolimus) , by Region USD Million (2025-2030)
  • Table 220. Kidney Cancer Drugs Votrient (Pazopanib) , by Region USD Million (2025-2030)
  • Table 221. Kidney Cancer Drugs Avastin (Bevacizumab) , by Region USD Million (2025-2030)
  • Table 222. Kidney Cancer Drugs Inlyta (Axitinib) , by Region USD Million (2025-2030)
  • Table 223. Kidney Cancer Drugs Torisel (Temsirolimus) , by Region USD Million (2025-2030)
  • Table 224. Kidney Cancer Drugs Proleukin (Aldesleukin) , by Region USD Million (2025-2030)
  • Table 225. Kidney Cancer Drugs Other , by Region USD Million (2025-2030)
  • Table 226. Kidney Cancer Drugs: by Application(USD Million)
  • Table 227. Kidney Cancer Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 228. Kidney Cancer Drugs Clinics , by Region USD Million (2025-2030)
  • Table 229. Kidney Cancer Drugs Research Center , by Region USD Million (2025-2030)
  • Table 230. Kidney Cancer Drugs Other , by Region USD Million (2025-2030)
  • Table 231. Kidney Cancer Drugs: by Therapy(USD Million)
  • Table 232. Kidney Cancer Drugs Targeted Therapy , by Region USD Million (2025-2030)
  • Table 233. Kidney Cancer Drugs Chemotherapy , by Region USD Million (2025-2030)
  • Table 234. Kidney Cancer Drugs Immunotherapy , by Region USD Million (2025-2030)
  • Table 235. South America Kidney Cancer Drugs, by Country USD Million (2025-2030)
  • Table 236. South America Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 237. South America Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 238. South America Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 239. Brazil Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 240. Brazil Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 241. Brazil Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 242. Argentina Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 243. Argentina Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 244. Argentina Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 245. Rest of South America Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 246. Rest of South America Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 247. Rest of South America Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 248. Asia Pacific Kidney Cancer Drugs, by Country USD Million (2025-2030)
  • Table 249. Asia Pacific Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 250. Asia Pacific Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 251. Asia Pacific Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 252. China Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 253. China Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 254. China Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 255. Japan Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 256. Japan Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 257. Japan Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 258. India Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 259. India Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 260. India Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 261. South Korea Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 262. South Korea Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 263. South Korea Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 264. Taiwan Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 265. Taiwan Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 266. Taiwan Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 267. Australia Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 268. Australia Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 269. Australia Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 270. Rest of Asia-Pacific Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 271. Rest of Asia-Pacific Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 272. Rest of Asia-Pacific Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 273. Europe Kidney Cancer Drugs, by Country USD Million (2025-2030)
  • Table 274. Europe Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 275. Europe Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 276. Europe Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 277. Germany Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 278. Germany Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 279. Germany Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 280. France Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 281. France Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 282. France Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 283. Italy Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 284. Italy Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 285. Italy Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 286. United Kingdom Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 287. United Kingdom Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 288. United Kingdom Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 289. Netherlands Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 290. Netherlands Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 291. Netherlands Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 292. Rest of Europe Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 293. Rest of Europe Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 294. Rest of Europe Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 295. MEA Kidney Cancer Drugs, by Country USD Million (2025-2030)
  • Table 296. MEA Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 297. MEA Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 298. MEA Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 299. Middle East Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 300. Middle East Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 301. Middle East Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 302. Africa Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 303. Africa Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 304. Africa Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 305. North America Kidney Cancer Drugs, by Country USD Million (2025-2030)
  • Table 306. North America Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 307. North America Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 308. North America Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 309. United States Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 310. United States Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 311. United States Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 312. Canada Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 313. Canada Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 314. Canada Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 315. Mexico Kidney Cancer Drugs, by Type USD Million (2025-2030)
  • Table 316. Mexico Kidney Cancer Drugs, by Application USD Million (2025-2030)
  • Table 317. Mexico Kidney Cancer Drugs, by Therapy USD Million (2025-2030)
  • Table 318. Kidney Cancer Drugs Sales: by Type(K Units)
  • Table 319. Kidney Cancer Drugs Sales Nexavar (Sorafenib) , by Region K Units (2025-2030)
  • Table 320. Kidney Cancer Drugs Sales Sutent (Sunitinib) , by Region K Units (2025-2030)
  • Table 321. Kidney Cancer Drugs Sales Afinitor (Everolimus) , by Region K Units (2025-2030)
  • Table 322. Kidney Cancer Drugs Sales Votrient (Pazopanib) , by Region K Units (2025-2030)
  • Table 323. Kidney Cancer Drugs Sales Avastin (Bevacizumab) , by Region K Units (2025-2030)
  • Table 324. Kidney Cancer Drugs Sales Inlyta (Axitinib) , by Region K Units (2025-2030)
  • Table 325. Kidney Cancer Drugs Sales Torisel (Temsirolimus) , by Region K Units (2025-2030)
  • Table 326. Kidney Cancer Drugs Sales Proleukin (Aldesleukin) , by Region K Units (2025-2030)
  • Table 327. Kidney Cancer Drugs Sales Other , by Region K Units (2025-2030)
  • Table 328. Kidney Cancer Drugs Sales: by Application(K Units)
  • Table 329. Kidney Cancer Drugs Sales Hospitals , by Region K Units (2025-2030)
  • Table 330. Kidney Cancer Drugs Sales Clinics , by Region K Units (2025-2030)
  • Table 331. Kidney Cancer Drugs Sales Research Center , by Region K Units (2025-2030)
  • Table 332. Kidney Cancer Drugs Sales Other , by Region K Units (2025-2030)
  • Table 333. Kidney Cancer Drugs Sales: by Therapy(K Units)
  • Table 334. Kidney Cancer Drugs Sales Targeted Therapy , by Region K Units (2025-2030)
  • Table 335. Kidney Cancer Drugs Sales Chemotherapy , by Region K Units (2025-2030)
  • Table 336. Kidney Cancer Drugs Sales Immunotherapy , by Region K Units (2025-2030)
  • Table 337. South America Kidney Cancer Drugs Sales, by Country K Units (2025-2030)
  • Table 338. South America Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 339. South America Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 340. South America Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 341. Brazil Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 342. Brazil Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 343. Brazil Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 344. Argentina Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 345. Argentina Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 346. Argentina Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 347. Rest of South America Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 348. Rest of South America Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 349. Rest of South America Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 350. Asia Pacific Kidney Cancer Drugs Sales, by Country K Units (2025-2030)
  • Table 351. Asia Pacific Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 352. Asia Pacific Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 353. Asia Pacific Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 354. China Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 355. China Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 356. China Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 357. Japan Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 358. Japan Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 359. Japan Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 360. India Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 361. India Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 362. India Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 363. South Korea Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 364. South Korea Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 365. South Korea Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 366. Taiwan Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 367. Taiwan Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 368. Taiwan Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 369. Australia Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 370. Australia Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 371. Australia Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 372. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 373. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 374. Rest of Asia-Pacific Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 375. Europe Kidney Cancer Drugs Sales, by Country K Units (2025-2030)
  • Table 376. Europe Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 377. Europe Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 378. Europe Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 379. Germany Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 380. Germany Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 381. Germany Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 382. France Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 383. France Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 384. France Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 385. Italy Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 386. Italy Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 387. Italy Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 388. United Kingdom Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 389. United Kingdom Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 390. United Kingdom Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 391. Netherlands Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 392. Netherlands Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 393. Netherlands Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 394. Rest of Europe Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 395. Rest of Europe Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 396. Rest of Europe Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 397. MEA Kidney Cancer Drugs Sales, by Country K Units (2025-2030)
  • Table 398. MEA Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 399. MEA Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 400. MEA Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 401. Middle East Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 402. Middle East Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 403. Middle East Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 404. Africa Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 405. Africa Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 406. Africa Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 407. North America Kidney Cancer Drugs Sales, by Country K Units (2025-2030)
  • Table 408. North America Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 409. North America Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 410. North America Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 411. United States Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 412. United States Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 413. United States Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 414. Canada Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 415. Canada Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 416. Canada Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 417. Mexico Kidney Cancer Drugs Sales, by Type K Units (2025-2030)
  • Table 418. Mexico Kidney Cancer Drugs Sales, by Application K Units (2025-2030)
  • Table 419. Mexico Kidney Cancer Drugs Sales, by Therapy K Units (2025-2030)
  • Table 420. Kidney Cancer Drugs: by Type(USD/Units)
  • Table 421. Research Programs/Design for This Report
  • Table 422. Key Data Information from Secondary Sources
  • Table 423. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kidney Cancer Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Kidney Cancer Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Kidney Cancer Drugs: by Therapy USD Million (2018-2023)
  • Figure 7. South America Kidney Cancer Drugs Share (%), by Country
  • Figure 8. Asia Pacific Kidney Cancer Drugs Share (%), by Country
  • Figure 9. Europe Kidney Cancer Drugs Share (%), by Country
  • Figure 10. MEA Kidney Cancer Drugs Share (%), by Country
  • Figure 11. North America Kidney Cancer Drugs Share (%), by Country
  • Figure 12. Global Kidney Cancer Drugs: by Type K Units (2018-2023)
  • Figure 13. Global Kidney Cancer Drugs: by Application K Units (2018-2023)
  • Figure 14. Global Kidney Cancer Drugs: by Therapy K Units (2018-2023)
  • Figure 15. South America Kidney Cancer Drugs Share (%), by Country
  • Figure 16. Asia Pacific Kidney Cancer Drugs Share (%), by Country
  • Figure 17. Europe Kidney Cancer Drugs Share (%), by Country
  • Figure 18. MEA Kidney Cancer Drugs Share (%), by Country
  • Figure 19. North America Kidney Cancer Drugs Share (%), by Country
  • Figure 20. Global Kidney Cancer Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Global Kidney Cancer Drugs share by Players 2023 (%)
  • Figure 22. Global Kidney Cancer Drugs share by Players (Top 3) 2023(%)
  • Figure 23. Global Kidney Cancer Drugs share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2023
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 37. Active Biotech (Sweden) Revenue, Net Income and Gross profit
  • Figure 38. Active Biotech (Sweden) Revenue: by Geography 2023
  • Figure 39. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 40. Amgen (United States) Revenue: by Geography 2023
  • Figure 41. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 42. Cipla Limited (India) Revenue: by Geography 2023
  • Figure 43. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 45. Global Kidney Cancer Drugs: by Type USD Million (2025-2030)
  • Figure 46. Global Kidney Cancer Drugs: by Application USD Million (2025-2030)
  • Figure 47. Global Kidney Cancer Drugs: by Therapy USD Million (2025-2030)
  • Figure 48. South America Kidney Cancer Drugs Share (%), by Country
  • Figure 49. Asia Pacific Kidney Cancer Drugs Share (%), by Country
  • Figure 50. Europe Kidney Cancer Drugs Share (%), by Country
  • Figure 51. MEA Kidney Cancer Drugs Share (%), by Country
  • Figure 52. North America Kidney Cancer Drugs Share (%), by Country
  • Figure 53. Global Kidney Cancer Drugs: by Type K Units (2025-2030)
  • Figure 54. Global Kidney Cancer Drugs: by Application K Units (2025-2030)
  • Figure 55. Global Kidney Cancer Drugs: by Therapy K Units (2025-2030)
  • Figure 56. South America Kidney Cancer Drugs Share (%), by Country
  • Figure 57. Asia Pacific Kidney Cancer Drugs Share (%), by Country
  • Figure 58. Europe Kidney Cancer Drugs Share (%), by Country
  • Figure 59. MEA Kidney Cancer Drugs Share (%), by Country
  • Figure 60. North America Kidney Cancer Drugs Share (%), by Country
  • Figure 61. Global Kidney Cancer Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Abbott Laboratories (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Novartis AG (Switzerland)
  • Merck KGaA (Germany)
  • Bayer AG (Germany)
  • Active Biotech (Sweden)
  • Amgen (United States)
  • Cipla Limited (India)
  • Roche Holding AG (Switzerland)
Additional players considered in the study are as follows:
Genentech (United States) , Prometheus Laboratories (United States) , Exelixis Inc. (United States) , AVEO Oncology (United States) , Immatics Biotechnologies (Germany)
Select User Access Type

Key Highlights of Report


Mar 2024 238 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Kidney Cancer Drugs Quantitative research analysis
Global Kidney Cancer Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Abbott Laboratories (United States), GlaxoSmithKline PLC (United Kingdom), Novartis AG (Switzerland), Merck KGaA (Germany), Bayer AG (Germany), Active Biotech (Sweden), Amgen (United States), Cipla Limited (India) and Roche Holding AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the Kidney Cancer Treatment" is seen as one of major influencing trends for Kidney Cancer Drugs Market during projected period 2023-2030.
The Kidney Cancer Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Kidney Cancer Drugs Report?

Have a Query? Click Here

Other Related Reports

Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), ...
$ 3750
Plant Sterol Esters Comprehensive Study by Type (Oil, Powder), End Users (Food & Beverages, Dairy Products, Pharmaceutical, Cosmetics) Players and Region - Global Market Outlook to 2026
$ 3500
Companion Diagnostics Comprehensive Study by End-users (Pharma Companies, Reference Laboratories, CRO, Others), Product & Service (Assay kits & Reagents, Software & Services), Technology Type (Polyme...
$ 3750
Vaccines & Vaccination Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Application (Pediatrics disease, Adults disease), Route of Administration (Intramuscular and Subcutaneo...
$ 3750
Dog Calcium Supplement Comprehensive Study by Application (Households, Veterinary Hospitals, Pet Cannels, Other), Form (Powder, Paste, Liquid, Capsules, Other), Distribution Channel (Online, Offline)...
$ 3800
Quinine Sulphate Comprehensive Study by Application (Malaria, Problematic Leg Cramps, Other), Distribution Chanel (Online, Offline), Dose (200mg, 300mg, Other) Players and Region - Global Market Outl...
$ 3500